BioLattice

BioLattice is a development-stage tissue engineering company that bridges the gap between academia and industry. The company specializes in rescuing dormant assets from leading universities, developing and de-risking these technologies through pre-clinical validation, and then licensing the intellectual property to industry partners. BioLattice aims to transform innovative ideas into medical products that expand patient access to solutions for restoring, repairing, or rebuilding damaged tissue. The company operates in the biotechnology and healthcare market, primarily serving medical institutions, research organizations, and industry partners focused on tissue engineering and regenerative medicine. BioLattice's business model revolves around identifying promising academic research, advancing it to a stage where it is commercially viable, and then monetizing it through licensing agreements. This approach allows the company to generate revenue while minimizing the risks associated with early-stage medical research and development.

Keywords: tissue engineering, regenerative medicine, pre-clinical validation, intellectual property, academia-industry bridge, medical products, biotechnology, healthcare, licensing, innovation.